Jeroen B.  Van Beek net worth and biography

Jeroen Van Beek Biography and Net Worth

Insider of AlloVir
eroen van Beek, Ph.D., has served as our Chief Commercial Officer since January 2019. Before joining AlloVir, Dr. van Beek was the Chief Commercial Officer and Senior Vice-President at Tricida in charge of commercial strategy, planning and operations from January 2018 to September 2018. From 2007 to 2017, Dr. van Beek worked at Alexion Pharmaceuticals, most recently as the Vice-President of Global Commercial Operations and Development in charge of the global Soliris® franchise. He was also responsible for the lifecycle management of Soliris® and the commercial development and positioning of Alexion’s portfolio of next-generation complement inhibitors.

During his tenure at Alexion, Dr. van Beek led the launches for Soliris® in two rare diseases: the blood disorder Paroxysmal Nocturnal Hemoglobinuria and the kidney disease atypical Hemolytic Uremic Syndrome.

From 1999 to 2007, Dr. van Beek held positions of increasing commercial responsibility at Pfizer including Marketing Director, Oncology responsible for launching Sutent® for renal cell carcinoma and gastrointestinalstromal tumor.

Dr. van Beek received his B.S. in Chemistry from the University of Virginia, his Ph.D. in Chemistry from Cornell University, and his M.B.A.from the Darden Business School at the University of Virginia.

What is Jeroen B. Van Beek's net worth?

The estimated net worth of Jeroen B. Van Beek is at least $162,950.30 as of November 10th, 2022. Dr. Van Beek owns 16,799 shares of AlloVir stock worth more than $162,950 as of January 28th. This net worth estimate does not reflect any other investments that Dr. Van Beek may own. Learn More about Jeroen B. Van Beek's net worth.

How do I contact Jeroen B. Van Beek?

The corporate mailing address for Dr. Van Beek and other AlloVir executives is 139 MAIN STREET SUITE 500, CAMBRIDGE MA, 02142. AlloVir can also be reached via phone at 617-433-2605 and via email at [email protected]. Learn More on Jeroen B. Van Beek's contact information.

Has Jeroen B. Van Beek been buying or selling shares of AlloVir?

Jeroen B. Van Beek has not been actively trading shares of AlloVir within the last three months. Learn More on Jeroen B. Van Beek's trading history.

Who are AlloVir's active insiders?

AlloVir's insider roster includes Ercem Atillasoy (Insider), Jeffrey Bornstein (Director), Brett Hagen (CAO), David Hallal (Director), Morana Jovan-Embiricos (Director), Ann Leen (Insider), Agustin Melian (Insider), Jeroen Van Beek (Insider), Juan Vera (Director), and John Wilson (Director). Learn More on AlloVir's active insiders.

Are insiders buying or selling shares of AlloVir?

In the last year, insiders at the sold shares 51 times. They sold a total of 8,688 shares worth more than $139,557.93. The most recent insider tranaction occured on January, 23rd when General Counsel Edward Miller sold 52 shares worth more than $494.00. Insiders at AlloVir own 32.1% of the company. Learn More about insider trades at AlloVir.

Information on this page was last updated on 1/23/2025.

Jeroen B. Van Beek Insider Trading History at AlloVir

See Full Table

Jeroen B. Van Beek Buying and Selling Activity at AlloVir

This chart shows Beek Jeroen B. Van's buying and selling at AlloVir by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

AlloVir Company Overview

AlloVir logo
AlloVir, Inc. engages in the research, development and commercialization of off-the-shelf VST therapies to prevent and treat severe viral-associated diseases. It develops novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems. The firm's technology platforms deliver commercially scalable solutions by leveraging off-the-shelf, allogeneic, multi-virus specific T-cells targeting devastating viral pathogens for immunocompromised patients under viral attack. The company was founded by Malcolm K. Brenner, Juan F. Vera, Helen E. Heslop, Cliona M. Rooney, John R. Wilson, and Ann M. Leen in August 2013 and is headquartered in Waltham, MA.
Read More

Today's Range

Now: $9.70
Low: $9.37
High: $10.40

50 Day Range

MA: $10.81
Low: $8.77
High: $13.28

2 Week Range

Now: $9.70
Low: $7.96
High: $24.15

Volume

59,637 shs

Average Volume

42,367 shs

Market Capitalization

$48.79 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.65